Market capitalization | $18.32m |
Enterprise Value | $-6.62m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.47 |
EV/Sales (TTM) EV/Sales | -5.05 |
P/S ratio (TTM) P/S ratio | 13.98 |
P/B ratio (TTM) P/B ratio | 0.83 |
Revenue growth (TTM) Revenue growth | 130.31% |
Revenue (TTM) Revenue | $1.31m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a Aprea Therapeutics Inc forecast:
3 Analysts have issued a Aprea Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 1.31 1.31 |
130%
130%
|
|
Gross Profit | 1.29 1.29 |
-
|
|
EBITDA | -15 -15 |
2%
2%
|
EBIT (Operating Income) EBIT | -15 -15 |
2%
2%
|
Net Profit | -14 -14 |
2%
2%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aprea Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wenji Bao in 2002 and is headquartered in Boston, MA.
Head office | United States |
CEO | Oren Gilad |
Employees | 7 |
Founded | 2002 |
Website | www.aprea.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.